Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5457539 | 0.99 | TAAR1 (0.50) | TAAR1ADRA1ACD274HTR2AHTR2C | |
| SCHEMBL5498157 | 0.88 | TAAR1 (0.52) | TAAR1ADRA1AHTR2AHTR2C | |
| SCHEMBL5502595 | 0.84 | TAAR1 (0.47) | TAAR1ADRA1AHTR2AHTR2CHTR2B | |
| SCHEMBL5501635 | 0.84 | SLC6A4 (0.58) | HTR2AMAPT | |
| SCHEMBL5502055 | 0.83 | TAAR1 (0.44) | TAAR1ADRA1AHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5281553 | 0.82 | SLC6A4 (0.57) | HTR2AMAPT | |
| SCHEMBL5501246 | 0.82 | TAAR1 (0.50) | TAAR1ADRA1AHTR2A | |
| SCHEMBL5503523 | 0.79 | TAAR1 (0.43) | TAAR1ADRA1AHTR2AHTR2CHTR2B | |
| SCHEMBL5502007 | 0.78 | TAAR1 (0.52) | TAAR1ADRA1AHTR2AHTR2CHTR2B | |
| SCHEMBL5501939 | 0.76 | TAAR1 (0.50) | TAAR1ADRA1AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | claimed |
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | TAAR1 283/4885ADRA1A 512/4885CD274 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.